Press Room

Visit our press room for current and past releases about our company.
July 15, 2015

Dr. Anahita Keyhani Joins Algorithme Pharma Laboratory Leadership as Director, Method Development

Algorithme Pharma, a full service provider focused on early stage clinical research with over twenty years of experience, proudly announces the addition of Dr. Anahita Keyhani to the Algorithme Pharma family.  Dr. Keyhani brings almost two decades of experience to her new role as Director, Method Development, previously Senior Research Scientist at Charles River Laboratories.

March 19, 2015

Algorithme Pharma — Proud Member of the Clinical Data Interchanges Standards Consortium

Algorithme Pharma, an Altasciences company, is now a proud member of the Clinical Data Interchanges Standards Consortium (CDISC), a non-profit organization harmonizing clinical data and streamlining research processes, from protocol through analysis and reporting, including the use of electronic health records to facilitate the collection of high quality research data.

March 05, 2015

Altasciences and ITR Laboratories Form a Strategic Alliance

Altasciences, a provider of early phase clinical research services, and ITR Laboratories, a nonclinical services organization announced today their strategic alliance offering clients a way to customize their drug development programs from lead candidate selection through to early stage clinical trials. This alliance facilitates working with a single integrated partner in order to bring drug candidates to proof of concept faster, and reduce costs.

February 19, 2015

CRO Leadership Awards — Altasciences Recognized for Leadership

Altasciences is pleased to announce that its companies, Algorithme Pharma (Montreal, Canada) and Vince & Associates Clinical Research (Kansas, USA), are both 2015 CRO Leadership Award recipients. 

February 10, 2015

Algorithme Pharma USA has its First Studies Underway

Last October, Altasciences expanded into the United States with the opening of Algorithme Pharma USA, in Fargo, North Dakota. Today, we are pleased to announce that our first studies were initiated and completed in January, just 91 days from the US contract being signed, and despite the holiday hustle.